Johnson & Johnson (JNJ) Cut to “Sell” at Vetr

Vetr lowered shares of Johnson & Johnson (NYSE:JNJ) from a hold rating to a sell rating in a research note issued to investors on Thursday morning. They currently have $124.55 price objective on the stock.

A number of other analysts have also recently issued reports on JNJ. Zacks Investment Research cut Johnson & Johnson from a buy rating to a hold rating in a report on Tuesday, December 12th. BMO Capital Markets boosted their target price on Johnson & Johnson to $161.00 and gave the stock an outperform rating in a report on Tuesday, December 12th. JPMorgan Chase cut Johnson & Johnson from an overweight rating to a neutral rating in a report on Tuesday, January 2nd. Royal Bank of Canada reiterated a buy rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Finally, Wells Fargo reiterated an outperform rating and set a $160.00 target price (up previously from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Five analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus price target of $144.58.

How to Become a New Pot Stock Millionaire

Shares of NYSE:JNJ opened at $128.10 on Thursday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12. Johnson & Johnson has a 1 year low of $120.95 and a 1 year high of $148.32. The stock has a market cap of $343,679.78, a PE ratio of 17.55, a PEG ratio of 2.04 and a beta of 0.74.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The business had revenue of $20.20 billion during the quarter, compared to analysts’ expectations of $20.08 billion. During the same quarter in the previous year, the business earned $1.58 EPS. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. sell-side analysts forecast that Johnson & Johnson will post 8.11 EPS for the current year.

In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the transaction, the vice president now directly owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.22% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Goodman Financial Corp acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at approximately $104,000. Harding Loevner LP acquired a new stake in shares of Johnson & Johnson during the 2nd quarter valued at approximately $106,000. Stelac Advisory Services LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at approximately $108,000. IHT Wealth Management LLC raised its position in shares of Johnson & Johnson by 46.4% during the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after acquiring an additional 3,467 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc acquired a new stake in shares of Johnson & Johnson during the 2nd quarter valued at approximately $124,000. 67.23% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Johnson & Johnson (JNJ) Cut to “Sell” at Vetr” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with's FREE daily email newsletter.

Leave a Reply